Mycozal (Fluconazole)

Fluconazole, the active ingredient in Mycozal, is an azole antifungal presented as an injection solution for intravenous use. It treats systemic fungal infections such as candidemia, invasive candidiasis, cryptococcal meningitis, and esophageal candidiasis in adult patients.

GNH USA supplies Mycozal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with European Union quality standards and is distributed under strict Good Distribution Practice to ensure potency and safety across global markets.

Mycozal (fluconazole) is used to treat systemic fungal infections within the azole antifungal class. - Candidemia: eradicates bloodstream Candida species, reducing mortality in adult patients. - Invasive candidiasis: clears deep‑tissue Candida infections, including organ involvement. - Cryptococcal meningitis: penetrates the central nervous system to treat Cryptococcus neoformans meningitis. - Esophageal candidiasis: resolves mucosal Candida infection causing painful swallowing.

Fluconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Headache: transient cranial discomfort reported during therapy. - Abdominal pain: discomfort or cramping in the stomach region. - Rash: skin erythema or mild itching. - Elevated liver enzymes: transient increase in hepatic transaminases. - Fever: low‑grade temperature elevation without infection.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring discontinuation. - Anaphylaxis: rapid, life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin and mucous membrane detachment. - Cardiac arrhythmia: QT prolongation leading to irregular heart rhythm. - Severe neutropenia: marked reduction in white blood cells. - Hepatic failure: acute liver failure with jaundice and coagulopathy.

Prior to initiating Mycozal, clinicians should evaluate several safety considerations to minimise risk. - Renal impairment: adjust dosing and monitor renal function closely. - Hepatic impairment: use with caution and observe liver enzyme trends. - Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Pediatric use: limited data; prescribe only when clearly indicated. - Drug interactions: review concomitant medications for potential CYP interactions. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Fluconazole interacts with several medicines through cytochrome P450 inhibition or induction, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect leading to bleeding risk. - Cisapride or terfenadine: heightened risk of life‑threatening QT prolongation. - Certain statins (e.g., simvastatin): elevated plasma levels causing myopathy.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing fluconazole efficacy. - Phenytoin or carbamazepine: may lower fluconazole concentrations. - Oral hypoglycemics (e.g., sulfonylureas): enhanced hypoglycaemic effect.